Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
The European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy presents an engaging and interactive course to improve the professional knowledge and skills for cardiovascular pharmacotherapy in older patients.
In Europe and the Western World in particular, the proportion of older persons is dramatically increasing, which is predicted to add tremendous extra pressure to the strained health care systems.
Cardiovascular drugs are among the most prevalent drugs administered to older people. In particular diuretics, antihypertensives, NOACs, antiarrhythmics, lipid lowering drugs and glucose lowering drugs. All these drug classes can lead to increased frailty and should in particular not be prescribed on a one-size-fits-all-basis to older people, and polypharmacy should be countered.
Our goal is for all participants to leave the meeting with the improved competence and confidence to deliver better, personalized therapy of older people, which in turn will have a positive impact on services and patient outcomes.
The programme is subject to change.
Demographical developments and feasibility of treating older patients in a short stay unit- “The Elderly” trial
Drug metabolism in older people
The problem of Hypo- and hyperkalemia in older people
Anti-hypertensive treatment in older patients
Therapeutic decisions in the elderly
LIPID LOWERING DRUGS
Lipid lowering agent selection in the elderly
GLUCOSE LOWERING DRUGS
Tight glycemic control, pros and cons [Debate]
DOACS IN AF STROKE PREVENTION
The use of DOACs in older individuals
Guidelines & beyond
Problems with polypharmacy in older people
The course will be held in Madrid, Spain.
Further details will be available in May.
Registration will open in May.
Registration fees are inclusive of applicable local VAT.
For any questions, please contact us on email@example.com
This course is organised by the ESC Working Group on Cardiovascular Pharmacotherapy. Not member yet? Join today
Reduction of cardiovascular disease burden by pharmacotherapy is a multistep approach, which requires:
Older patients with cardiovascular disease are often shown to be undertreated. Among others, main reasons are polypharmacotherapy and thus fear for side effects, and sparse evidence from trials in this subgroup due to limited enrolment. Therefore, the older subgroup of patients with CV disease represents the ideal population who may benefit from strategies leading to implement the optimised use of pharmacotherapy.
The specific aim of this course is to improve competence and confidence to deliver better, personalized therapy of older people, which in turn will have a positive impact on implementing use of services and pharmacotherapy and thus patient outcomes.
POP courses are dedicated to physicians dealing with hospital admissions, ward and outpatient consultations
The first course on Pharmacotherapy in Older People took place in October 2019 in London, with over 40 participants for the launch.
Access the resources
European Society of Cardiology
European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot
06903, Sophia Antipolis, FR
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.